[시장보고서]세계의 인간 마이크로바이옴 시장 : 제품별, 질환별, 유형별, 최종 사용자별 예측(-2030년)

세계의 인간 마이크로바이옴 시장 : 제품별, 질환별, 유형별, 최종 사용자별 예측(-2030년)

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030

상품코드 : 1563533 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2024년 09월

페이지 정보 : 영문 291 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 6,967,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,359,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,471,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,075,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계의 인간 마이크로바이옴 시장 규모는 2024년 8억 1,460만 달러에서 2030년까지 42억 600만 달러에 이를 것으로 예측되며, 예측 기간에 복합 연간 성장률(CAGR) 31.5%의 성장이 예상됩니다.

조사 범위
조사 대상년도	2022년-2030년
기준년	2023년
예측 기간	2024년-2030년
단위	100만 달러
부문	제품별, 질병별, 유형별, 최종 사용자별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

마이크로바이옴 연구를 위한 마이크로바이옴 산업과 학계의 협력 체제와 맞춤형 의료에 대한 수요 증가 등의 요인이 인간 마이크로바이옴 시장의 성장을 가속하고 있습니다. 그러나 복잡한 규제 정책은 마이크로바이옴의 상업화에 악영향을 미치고 시장 성장을 억제하고 있습니다.

"제품 부문별로 프로바이오틱스 부문은 2023년 시장에서 가장 큰 점유율을 차지했습니다."

2023년 인간 마이크로바이옴 시장에서 가장 큰 점유율을 차지하는 부문은 프로바이오틱스이며, 이는 장의 건강, 면역력 및 전반적인 건강에 대한 프로바이오틱스의 이점에 대한 소비자 의식 증가로 인한 것 입니다. 덧붙여 프리바이오틱스 부문은 2위 시장 점유율을 차지했습니다. 또한, 프로바이오틱스의 건강 강조표시를 뒷받침하는 활발한 연구와 함께, 건강 보충제로서 소비자 수요와 수용이 확산되고 있는 것도, 같은 부문의 성장을 지지하고 있습니다. 또, 프로바이오틱스를 포함한 기능성 식품이나 식품 및 음료의 인기가 높아지고 있는 것도 시장을 뒷받침하고 있습니다.

"아시아태평양이 2024년-2030년에 시장에서 가장 높은 복합 연간 성장률(CAGR)로 성장하고 있습니다."

아시아태평양은 주로 마이크로바이옴의 건강에 대한 의식이 높아지고, 신흥의 의료,바이오테크놀러지 산업, 정부의 지원, 맞춤형 의료에 대한 자금 조달의 가능성에 의해 시장에서 가장 급성장하는 부문이 될 것으로 추정됩니다. 고정밀 시퀀싱 기술의 개발은 한 샘플에서 마이크로바이옴 전체 시퀀싱을 가능하게 하고, 연구자들은 샘플에 존재하는 미생물 군집을 보다 정확하고 종합적으로 특성화할 수 있게 되었습니다. 데이터 보호와 프라이버시 측면에서의 과제와 인간 우유 생물의 높은 비용은 아시아태평양 시장의 성장을 억제할 것으로 예상됩니다. 또한 지역에 따라 문화적, 언어적 장벽이 있어 마이크로바이옴 시퀀싱 데이터의 정확성과 임상적 유용성에 대한 우려도 있습니다.

이 보고서는 세계의 인간 마이크로 바이옴 시장에 대한 조사 분석을 통해 주요 촉진요인과 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.

소개
시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 과제
고객의 비즈니스에 영향을 미치는 동향/혼란
가격 분석
- 인간 마이크로 바이옴 의약품의 평균 판매 가격 : 주요 기업별
- 인간 마이크로바이옴 제품의 평균 비용 범위(2021년-2023년)
- 평균 판매 가격 분석 : 지역별
파이프라인 분석
특허 분석
생태계 분석
공급망 분석
밸류체인 분석
인간 마이크로바이옴 시장에 대한 AI/생성형 AI의 영향
기술 분석
- 주요 기술
- 보완 기술
- 인접 기술
주된 회의와 이벤트(2024년-2025년)
규제 분석
- 규제 상황
- 규제기관, 정부기관, 기타 조직
Porter's Five Forces 분석
주요 이해관계자와 구매 기준
사례 연구 분석
투자와 자금조달 시나리오

제6장 인간 마이크로바이옴 시장 : 제품별

소개
의약품
프로바이오틱스
프리바이오틱스
신바이오틱스

제7장 인간 마이크로바이옴 시장 : 질환별

소개
감염증
위장질환
내분비,대사장애
기타 질환

제8장 인간 마이크로바이옴 시장 : 유형별

소개
세균 컨소시엄 이식(BCT)/분변 미생물 이식(FMT)
생균제제(LBP)
기타 마이크로바이옴의 유형

제9장 인간 마이크로바이옴 시장 : 투여 경로별

소개
경구 투여
경직장 투여

제10장 인간 마이크로바이옴 시장 : 최종 사용자별

소개
병원 및 진료소
장기 케어 시설
기타 최종 사용자

제11장 인간 마이크로바이옴 시장 : 지역별

소개
북미
- 북미의 거시경제 전망
- 미국
- 캐나다
유럽
- 유럽의 거시 경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 아시아태평양의 거시 경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
라틴아메리카
- 라틴아메리카의 거시 경제 전망
- 브라질
- 기타 라틴아메리카
중동
- 중동의 거시 경제 전망
- GCC 국가
- 기타 중동
아프리카

제12장 경쟁 구도

소개
- 주요 기업의 전략/유력 기업
- 인간 마이크로바이옴 시장의 주요 기업이 채용하고 있는 전략의 개요
수익 분석(2021년-2023년)
시장 점유율 분석(2023년)
기업의 평가 매트릭스: 주요 기업(2023년)
기업의 평가 매트릭스: 스타트업/중소기업(2023년)
기업 평가 및 재무 지표
브랜드/제품 비교
경쟁 시나리오

제13장 기업 프로파일

주요 기업
- INTERNATIONAL FLAVORS & FRAGRANCES, INC.
- SEED HEALTH, INC.
- PENDULUM
- SERES THERAPEUTICS
- FERRING PHARMACEUTICALS
- BIOMEBANK
- BIOHM HEALTH INC.
- ACTIAL FARMACEUTICA SRL
- OPTIBIOTIX HEALTH PLC
- RESBIOTIC
- INFINANT HEALTH INC.
- BIOGAIA AB
- EXEGI PHARMA, LLC
기타 기업
- AOBIOME
- GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
- NUBIYOTA
- OXTHERA AB
- NEXBIOME
- VEDANTA BIOSCIENCES, INC.
- ENTEROME
- APSEN FARMACEUTICA SA
- METAGEN THERAPEUTICS, INC.
- SNIPR BIOME
- MAAT PHARMA SA
- MIKROBIOMIK

제14장 부록

BJH

영문 목차

영문목차

The Human Microbiome market is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.

Scope of the Report
Years Considered for the Study	2022-2030
Base Year	2023
Forecast Period	2024-2030
Units Considered	Value (USD Million)
Segments	By Products, Disease, Type, and End Users
Regions covered	North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the Human Microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.

"The probiotics segment accounted for the largest share by product segment in the human microbiome market in 2023."

The market is analyzed across four key products: drugs, probiotics, prebiotics, and synbiotics. The segment with the biggest share in the Human Microbiome market in 2023 is Probiotics, Driven by increasing consumer awareness about the benefits of probiotics for gut health, immunity, and overall wellness. Still, the Prebiotics segment held the second-largest market share. Additionally, widespread consumer demand and acceptance as health supplements along with active research supporting health claims on probiotics supports the segment growth. The market is also propelled by the growing popularity of functional foods and beverages containing probiotics.

"The Asia Pacific region is growing at the highest CAGR in the human microbiome market from 2024 to 2030."

The Asia Pacific is estimated to be the fastest-growing segment of the market primarily due to the increasing awareness of microbiome health, emerging healthcare and biotechnology industries, government support, and funding potential for personalized medicine. The development of high - throughout sequencing technologies has made it possible to sequence the entire mircrobiome in a single sample, enabling researchers to more accurately and comprehensively characterize the microbial communities that are present in samples. Challenges in terms of data protection and privacy, as well as high cost of human mircrobiomes, are expected to restrain the growth of the Asia- pacific market. In addition, there may be cultural and linguistic barriers to adoption in certain region, as well as concerns about the accuracy and clinical utility of microbiome sequencing data.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: Executives - 25%, CXOs - 30%, and Managers - 45%
By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa -5%..

List of Companies Profiled in the Report:

Nestle S.A. (Switzerland)
Ferring Pharmaceuticals (Switzerland)
BiomeBank (Australia)
Seed Health, Inc. (US)
International Flavors & Fragrances Inc (US)
Pendulum (US)
BioHM Health Inc. (US)
Actial Farmaceutica SRL (Italy)
Optibiotix Health plc (UK)
Resbiotic (US)
Infinant Health Inc (US)
Biogaia AB (Sweden)
Exegi Pharma Llc (US)

Research Coverage:

This research report categorizes the Human Microbiome market by Product (Drugs, Probiotics, Prebiotics, and others), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Biotherapeutic Products, and Others) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the Human Microbiome market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Start-Ups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.

Product Development/Innovation: Detailed insights on newly launched products of the Human Microbiome market
Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market
Competitive Assessment: Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infinant Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US) among others in the market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION
1.4 YEARS CONSIDERED
1.5 CURRENCY
1.6 RESEARCH LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
1.9 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 MARKET ESTIMATION
  - 2.2.1.1 Insights of primary experts
- 2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 HUMAN MICROBIOME MARKET OVERVIEW
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT AND COUNTRY (2023)
4.3 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2030)

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Collaborative initiatives between organizations and academia in microbiome industry
  - 5.2.1.2 Increasing number of start-ups/SMEs exploring microbiome niche
  - 5.2.1.3 Advancements in microbiome sequencing
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes
  - 5.2.2.2 High investments in commercialization of microbiome drugs
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Increasing demand for personalized medicine
  - 5.2.3.2 Emergence of postbiotics
- 5.2.4 CHALLENGES
  - 5.2.4.1 Slow patient adoption of microbiome-based therapies
  - 5.2.4.2 Complexities involved in development of microbiome therapies
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER
- 5.4.2 AVERAGE COST RANGE OF HUMAN MICROBIOME PRODUCTS, 2021-2023
- 5.4.3 AVERAGE SELLING PRICE ANALYSIS, BY REGION
5.5 PIPELINE ANALYSIS
5.6 PATENT ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 SUPPLY CHAIN ANALYSIS
5.9 VALUE CHAIN ANALYSIS
5.10 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
  - 5.11.1.1 Whole-genome sequencing
  - 5.11.1.2 16s RNA sequencing method
  - 5.11.1.3 Nanopore sequencing
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
  - 5.11.2.1 Metatranscriptomics
  - 5.11.2.2 Metagenomics
  - 5.11.2.3 Metabolomics
- 5.11.3 ADJACENT TECHNOLOGIES
  - 5.11.3.1 Sample preparation
  - 5.11.3.2 Data analysis
  - 5.11.3.3 Library synthesis
5.12 KEY CONFERENCES & EVENTS IN 2024-2025
5.13 REGULATORY ANALYSIS
- 5.13.1 REGULATORY LANDSCAPE
  - 5.13.1.1 North America
  - 5.13.1.2 Europe
  - 5.13.1.3 Asia Pacific
- 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER'S FIVE FORCES ANALYSIS
- 5.14.1 THREAT OF NEW ENTRANTS
- 5.14.2 THREAT OF SUBSTITUTES
- 5.14.3 BARGAINING POWER OF BUYERS
- 5.14.4 BARGAINING POWER OF SUPPLIERS
- 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.15.2 BUYING CRITERIA
5.16 CASE STUDY ANALYSIS
- 5.16.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
- 5.16.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION
- 5.16.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS.
5.17 INVESTMENT & FUNDING SCENARIO
- 5.17.1 OTHER INVESTMENTS AND FUNDING

6 HUMAN MICROBIOME MARKET, BY PRODUCT

6.1 INTRODUCTION
6.2 DRUGS
- 6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET
6.3 PROBIOTICS
- 6.3.1 GROWING CONSUMER AWARENESS ABOUT PROBIOTICS FOR IMPROVED GUT HEALTH AND IMMUNITY TO AID MARKET GROWTH
6.4 PREBIOTICS
- 6.4.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH
6.5 SYNBIOTICS
- 6.5.1 GROWING DEMAND FOR PERSONALIZED TREATMENT AND RISING INCIDENCE OF DYSBIOSIS TO AUGMENT MARKET GROWTH

7 HUMAN MICROBIOME MARKET, BY DISEASE

7.1 INTRODUCTION
7.2 INFECTIOUS DISEASES
- 7.2.1 EMERGENCE OF MULTI-DRUG-RESISTANT BACTERIA TO BOOST MARKET GROWTH
7.3 GASTROINTESTINAL DISEASES
- 7.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO PROPEL MARKET GROWTH
7.4 ENDOCRINE & METABOLIC DISORDERS
- 7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET GROWTH
7.5 OTHER DISEASES

8 HUMAN MICROBIOME MARKET, BY TYPE

8.1 INTRODUCTION
8.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
- 8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH
8.3 LIVE BIOTHERAPEUTIC PRODUCTS (LBP)
- 8.3.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET
8.4 OTHER MICROBIOME TYPES

9 HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION

9.1 INTRODUCTION
9.2 ORAL ROUTE OF ADMINISTRATION
- 9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO DRIVE MARKET GROWTH
9.3 RECTAL ROUTE OF ADMINISTRATION
- 9.3.1 PRODUCT APPROVALS AND EFFICACY IN TARGETED DELIVERY TO SUPPORT MARKET GROWTH

10 HUMAN MICROBIOME MARKET, BY END USER

10.1 INTRODUCTION
10.2 HOSPITALS & CLINICS
- 10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH
10.3 LONG-TERM CARE FACILITIES
- 10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
10.4 OTHER END USERS

11 HUMAN MICROBIOME MARKET, BY REGION

11.1 INTRODUCTION
11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 11.2.2 US
  - 11.2.2.1 Strong ecosystem backed by regulation, research, and funding to drive market
- 11.2.3 CANADA
  - 11.2.3.1 Government initiatives, independent organizations, and academia collaborations to boost microbiome research
11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 11.3.2 GERMANY
  - 11.3.2.1 Rapid increase in government and private funding to propel market
- 11.3.3 UK
  - 11.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth
- 11.3.4 FRANCE
  - 11.3.4.1 Growing awareness and rise of specialized organizations to boost growth
- 11.3.5 ITALY
  - 11.3.5.1 Government intervention and academic institutions to drive market growth
- 11.3.6 SPAIN
  - 11.3.6.1 Growing academic research initiatives to boost growth
- 11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 11.4.2 CHINA
  - 11.4.2.1 Increasing R&D investments to drive growth
- 11.4.3 JAPAN
  - 11.4.3.1 Growing geriatric population to present opportunities for market growth
- 11.4.4 INDIA
  - 11.4.4.1 Increasing prevalence of chronic diseases to support growth
- 11.4.5 SOUTH KOREA
  - 11.4.5.1 Increasing prevalence of chronic diseases to support growth
- 11.4.6 AUSTRALIA
  - 11.4.6.1 Growing number of product approvals to boost growth
- 11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 11.5.2 BRAZIL
  - 11.5.2.1 Rising probiotics demand to drive market
- 11.5.3 REST OF LATIN AMERICA
11.6 MIDDLE EAST
- 11.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
- 11.6.2 GCC COUNTRIES
  - 11.6.2.1 Saudi Arabia
    - 11.6.2.1.1 Increasing focus on R&D to boost market growth
  - 11.6.2.2 UAE
    - 11.6.2.2.1 Increasing focus on R&D and healthcare spending to boost market growth
  - 11.6.2.3 Rest of GCC countries
- 11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
- 11.7.1 STUDIES AND INITIATIVES TO BOOST MARKET GROWTH
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION
- 12.1.1 KEY PLAYER STRATEGY/RIGHT TO WIN
- 12.1.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET
12.2 REVENUE ANALYSIS, 2021-2023
12.3 MARKET SHARE ANALYSIS, 2023
12.4 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.4.1 STARS
- 12.4.2 EMERGING LEADERS
- 12.4.3 PERVASIVE PLAYERS
- 12.4.4 PARTICIPANTS
- 12.4.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
  - 12.4.5.1 Company footprint
  - 12.4.5.2 Product footprint
  - 12.4.5.3 Type footprint
  - 12.4.5.4 Disease footprint
  - 12.4.5.5 Region footprint
12.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.5.1 PROGRESSIVE COMPANIES
- 12.5.2 RESPONSIVE COMPANIES
- 12.5.3 DYNAMIC COMPANIES
- 12.5.4 STARTING BLOCKS
- 12.5.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.6 COMPANY VALUATION & FINANCIAL METRICS
12.7 BRAND/PRODUCT COMPARISON
12.8 COMPETITIVE SCENARIO
- 12.8.1 PRODUCT APPROVALS
- 12.8.2 DEALS

13 COMPANY PROFILES

13.1 KEY PLAYERS
- 13.1.1 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
  - 13.1.1.1 Business overview
  - 13.1.1.2 Products offered
  - 13.1.1.3 Recent developments
    - 13.1.1.3.1 Deals
  - 13.1.1.4 MnM view
    - 13.1.1.4.1 Key strengths
    - 13.1.1.4.2 Strategic choices
    - 13.1.1.4.3 Weaknesses & competitive threats
- 13.1.2 SEED HEALTH, INC.
  - 13.1.2.1 Business overview
  - 13.1.2.2 Products offered
  - 13.1.2.3 Recent developments
    - 13.1.2.3.1 Deals
  - 13.1.2.4 MnM view
    - 13.1.2.4.1 Key strengths
    - 13.1.2.4.2 Strategic choices
    - 13.1.2.4.3 Weaknesses & competitive threats
- 13.1.3 PENDULUM
  - 13.1.3.1 Business overview
  - 13.1.3.2 Products offered
  - 13.1.3.3 Recent developments
    - 13.1.3.3.1 Deals
  - 13.1.3.4 MnM view
    - 13.1.3.4.1 Key strengths
    - 13.1.3.4.2 Strategic choices
    - 13.1.3.4.3 Weaknesses & competitive threats
- 13.1.4 SERES THERAPEUTICS
  - 13.1.4.1 Business overview
  - 13.1.4.2 Products offered
  - 13.1.4.3 Recent developments
    - 13.1.4.3.1 Product approvals
    - 13.1.4.3.2 Deals
  - 13.1.4.4 MnM view
    - 13.1.4.4.1 Key strengths
    - 13.1.4.4.2 Strategic choices
    - 13.1.4.4.3 Weaknesses & competitive threats
- 13.1.5 FERRING PHARMACEUTICALS
  - 13.1.5.1 Business overview
  - 13.1.5.2 Products offered
  - 13.1.5.3 Recent developments
    - 13.1.5.3.1 Product approvals
    - 13.1.5.3.2 Deals
  - 13.1.5.4 MnM view
    - 13.1.5.4.1 Key strengths
    - 13.1.5.4.2 Strategic choices
    - 13.1.5.4.3 Weaknesses & competitive threats
- 13.1.6 BIOMEBANK
  - 13.1.6.1 Business overview
  - 13.1.6.2 Products offered
  - 13.1.6.3 Recent developments
    - 13.1.6.3.1 Product approvals
    - 13.1.6.3.2 Expansions
- 13.1.7 BIOHM HEALTH INC.
  - 13.1.7.1 Business overview
  - 13.1.7.2 Products offered
  - 13.1.7.3 Recent developments
    - 13.1.7.3.1 Deals
- 13.1.8 ACTIAL FARMACEUTICA SRL
  - 13.1.8.1 Business overview
  - 13.1.8.2 Products offered
- 13.1.9 OPTIBIOTIX HEALTH PLC
  - 13.1.9.1 Business overview
  - 13.1.9.2 Products offered
  - 13.1.9.3 Recent developments
    - 13.1.9.3.1 Product approvals
    - 13.1.9.3.2 Deals
- 13.1.10 RESBIOTIC
  - 13.1.10.1 Business overview
  - 13.1.10.2 Products offered
  - 13.1.10.3 Recent developments
    - 13.1.10.3.1 Expansions
- 13.1.11 INFINANT HEALTH INC.
  - 13.1.11.1 Business overview
  - 13.1.11.2 Products offered
- 13.1.12 BIOGAIA AB
  - 13.1.12.1 Business overview
  - 13.1.12.2 Products offered
  - 13.1.12.3 Recent developments
    - 13.1.12.3.1 Deals
    - 13.1.12.3.2 Expansions
- 13.1.13 EXEGI PHARMA, LLC
  - 13.1.13.1 Business overview
  - 13.1.13.2 Products offered
  - 13.1.13.3 Recent developments
    - 13.1.13.3.1 Deals
13.2 OTHER PLAYERS
- 13.2.1 AOBIOME
- 13.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
- 13.2.3 NUBIYOTA
- 13.2.4 OXTHERA AB
- 13.2.5 NEXBIOME
- 13.2.6 VEDANTA BIOSCIENCES, INC.
- 13.2.7 ENTEROME
- 13.2.8 APSEN FARMACEUTICA S.A.
- 13.2.9 METAGEN THERAPEUTICS, INC.
- 13.2.10 SNIPR BIOME
- 13.2.11 MAAT PHARMA SA
- 13.2.12 MIKROBIOMIK

14 APPENDIX

14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS